News & Events

• February 6, 2015
  

  European Medicines Agency Qualifies ‘Hollow Fiber System’ For Anti-Tuberculosis Drug Development

  February 6, 2015 European Medicines Agency Qualifies ‘Hollow Fiber System’ For Anti-Tuberculosis Drug Development Provides major boost for improved development of TB treatment to meet major public health challenge TUCSON, Ariz., February 6, 2015 – The Critical Path Institute (C-Path), an independent, nonprofit organization working to accelerate the process of drug and medical product development, announced......
• December 8, 2014
  

  Critical Path Institute Receives Third Grant To Accelerate Tuberculosis Diagnostics

  December 8, 2014  Critical Path Institute Receives Third Grant To Accelerate Tuberculosis Diagnostics Multi-Year Grant to Fund Innovative Global Data Platform Designed To Streamline Tuberculosis Diagnosis and Treatment TUCSON, Ariz., December 8, 2014 – Critical Path Institute (C-Path), an Arizona-based non-profit organization dedicated to fostering collaborative initiatives to improve the quality and efficiency of the......
• September 22, 2014
  

  Critical Path Institute Receives Second Grant for Advancing Tuberculosis Treatments

• February 4, 2014
  

  Critical Path Institute Receives Grant to Accelerate Development of Tuberculosis Treatments

• September 18, 2013
  

  CPTR Initiative Expands Focus to Include Drug Susceptibility Tests